Futura Announces Collaboration with Cooper Consumer Health to Commercialise MED3000 in EEA, United Kingdom and Switzerland
Futura Medical plc (AIM: FUM), a pharmaceutical company developing…
Novo Holdings Portfolio Company F2G enters strategic collaboration with Shionogi to commercialise its new antifungal agent Olorofim in Europe and Asia
Deal value includes upfront payment of US$100 million with…
DelSiTech and Anticancer Bioscience Announce a Collaboration Agreement for the Development of Long-acting Therapies in Oncology
Turku, Finland – 18 May 2022: DelSiTech Ltd, the leading silica…
Sofinnova Partners and Apollo form strategic partnership in life sciences
NEW YORK & PARIS (May 16, 2022) - Apollo (NYSE: APO) and Sofinnova…
Shionogi Co., Ltd. and F2G Enter Strategic Collaboration to Develop and Commercialize the New Antifungal Agent Olorofim in Europe and Asia
Shionogi to conduct clinical trials, subsequent registration,…
Destiny Pharma – World leading C. difficile scientists to present landmark data on the ability of NTCD-M3 to colonise the gut after antibiotic administration
Brighton, United Kingdom – 12 May 2022 – Destiny Pharma…
Rejuvenate Biomed appoints life sciences leader Dr. Ajit Shetty as Chair of the Board of Directors to help guide international ambitions
Diepenbeek, Belgium, 12 May 2022 – Rejuvenate Biomed NV (“Rejuvenate”),…
ImaginAb announces a new supply agreement with Invicro to offer clinical doses of CD8 investigational ImmunoPET imaging agent for Immuno-Oncology preclinical and clinical studies
Inglewood, California, May 12th, 2022 - ImaginAb Inc., a market-leading…
Novo Holdings backs animal health company Invetx
Novo Holdings today announces it has participated in a $60.5…
vasopharm GmbH Announces Brain Glutamate Microdialysate Data from Post Hoc Analyses of Clinical Trials in Traumatic Brain Injury
Ronopterin significantly reduces glutamate levels measured…
Novo Nordisk Foundation – Researchers mobilise to combat antimicrobial resistance
Antibiotics are used to treat or prevent some types of bacterial…
ImaginAb Announces New Supply Agreement to Supply Genmab A/S with its Investigational CD8 ImmunoPET Agent
Los Angeles, CA, USA, May 5th, 2022 – ImaginAb, Inc., a market…
AMSilk appoints Klaus Kjedal as Chief Production Officer and Managing Director
Munich, Germany, 04 May 2022 – AMSilk GmbH (“AMSilk”),…
Gadeta to Attend Upcoming Business and Investor Conferences
Utrecht, Netherlands and Boston, Mass., 4th May 2022: Gadeta…
Asceneuron Awarded Second Grant from The Michael J. Fox Foundation for Accelerated Research into Novel Parkinson’s Disease Therapies
Lausanne, SWITZERLAND and San Francisco, CA, USA, 4 May 2022…
We’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
Optimum Strategic Communications’ specialist team has an in-depth understanding of how to communicate complex science to investors and corporate stakeholders. Optimum helps life science companies on their journey as they grow and has been trusted by hundreds of healthcare clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York
